Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
• Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer
• Data presented at AACR 2024 shows MACO-355 is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions
• Data demonstrated Macomics’ ENIGMAC™ platform at-scale CRISPR screening for macrophage target discovery
Edinburgh and Cambridge, UK, 11 April 2024 - Macomics Ltd, a…
Access to compound collection enables greater flexibility and efficiencies in screening and target identification
Cambridge, UK and Kyiv, Ukraine, 11th April 2024: Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in supplying small molecules and early drug discovery services, announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine’s compound libraries.
The Enamine compound…
Read April's eNews
Growing Opportunities for our Network, featuring:
✅ Welcome from Tony Jones, CEO, One Nucleus
✅ Review of this year's BLSA (Building Life Science Adventures)
✅ Tony Jones reviews our Inaugural Annual Awards
✅ Boston Bootcamp Winners and What they Can Look Forward To
✅ BIO-Europe Spring - A review of Hot Topics and How to Maximise the Returns and Wellbeing
✅ Prepare for the BIO International Convention in San Diego
✅ Networking Event: Collaboration Opportunities in Puerto Rico for Life Sciences
Regulatory Compliant Tissue Microarrays
AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.
These high-quality tissue microarrays (TMAs) enable high-throughput analysis of a panel of tissue types recognized by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Each TMA features multiple normal tissue types from 3 different donor samples on a single slide to enable simultaneous analysis and facilitate the identification of potential cross-reactive and…
Astex Pharmaceuticals Announce Key Data Presentations at the American Association For Cancer Research (AACR) 2024 Annual Meeting
Cambridge, UK, 3 April 2023 – Astex Pharmaceuticals, a pharmaceutical company based in Cambridge, UK, dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it will make five key data presentations at AACR 2024 focusing on its Phase II-ready MDM2 antagonist, ASTX295. AACR 2024 will take place from April 5-10, 2024, at the San Diego Convention Center, San Diego,…
As technologies emerge that enable a wide range of naturally occurring medicinal compounds to be reproduced by a host plant within a controlled environment, is it time to review the use of plants as biofactories? Innovation facilitators Agri-TechE are partnering with the life-sciences network OneNucleus to explore the market potential of using plant factories to mass produce rare drugs. Find out more about the event here.
Contributing his expertise to the workshop is Malcolm Skingle, Director of Academic Liaison at GSK, who has seen the evolution of natural products over many…
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
Stevenage, UK, 26 March 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.
Ali has extensive experience in the biotechnology and pharma sector working with both private and public companies. She joins from Acacia Pharma Group plc, an early commercial-stage listed pharma company, where she was Group Financial…
• Leading precision medicine and nucleic acid therapy (NAT) innovators will harness their platforms to develop NAT drug candidates for novel gene targets with strong genetic association to sporadic ALS
• The programme will be supported by mechanism-based patient stratification biomarkers to identify likely responders and accelerate and derisk clinical development
OXFORD and HARWELL, UK – 26 March 2024 – The pioneering precision medicine company, PrecisionLife, and the MRC nucleic acid therapy research unit, NATA, today announce a collaboration to co-develop novel oligonucleotide therapies for…
Norwich Research Park showcased its latest collaborations with industry at its Enterprise Tuesday event held on Tuesday 5 March at the John Innes Conference Centre.
The event theme was ‘Problem solving through collaboration’ and featured a number of presentations by newly formed businesses that have emerged from research on the Park, a keynote speech from Innovate UK and a panel debate on ‘Preventative medicine, early intervention and healthy ageing’. The event was organised by Anglia Innovation Partnership, the science park management company at Norwich Research Park and was sponsored by…
Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced the winners of its second Innovation & Entrepreneurship Awards.
In the field of oncology, the translation of innovative science faces numerous hurdles. These include securing initial funding amid increasing R&D costs and the necessity to gather specialised expertise to navigate scientific, entrepreneurial, financial and market challenges. The Innovation & Entrepreneurship Awards aim to celebrate researchers and innovators actively bridging the gap between oncology discoveries and positive patient…